Extrafine triple therapy in patients with asthma and persistent airflow limitation
Eur Respir J
.
2020 Sep 24;56(3):2000476.
doi: 10.1183/13993003.00476-2020.
Print 2020 Sep.
Authors
Dave Singh
1
,
Johann Christian Virchow
2
,
Giorgio Walter Canonica
3
4
,
Andrea Vele
5
,
Maxim Kots
5
,
George Georges
5
,
Alberto Papi
6
Affiliations
1
Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK dsingh@meu.org.uk.
2
Universitätsmedizin Rostock, Zentrum für Innere Medizin, Abteilung für Pneumologie, Rostock, Germany.
3
Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.
4
Dept of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
5
Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
6
Section of Cardiorespiratory and Internal Medicine, Dept of Medical Sciences, University of Ferrara, Ferrara, Italy.
PMID:
32430414
DOI:
10.1183/13993003.00476-2020
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Anti-Asthmatic Agents* / therapeutic use
Asthma* / drug therapy
Humans
Lung
Substances
Anti-Asthmatic Agents
Associated data
ClinicalTrials.gov/NCT02676076
ClinicalTrials.gov/NCT02676089